JBIO Jade Biosciences, Inc.

Price Chart

Executive Summary

Jade Biosciences reported interim Phase 1 data for JADE101, an anti-APRIL antibody for IgAN. The data showed ~70% mean IgA reduction sustained at 12 weeks at the 700 mg dose, a favorable safety profile, and PK/PD modeling supports every-12-week subcutaneous maintenance dosing. This supports advancing to Phase 2 (JUNIPER, already started) and a planned registrational Phase 3 trial in 1H 2027. The positive clinical data de-risks the program and supports best-in-class positioning in a large $20B+ addressable market.

Actionable Insight

Key Facts

• Mean IgA reductions ~70% from baseline sustained at 12 weeks at 700 mg dose
• Phase 1 healthy volunteer trial (N=32): well-tolerated up to 1,400 mg, no serious adverse events, no discontinuations, no hypogammaglobulinemia
• IgA-lowering potency ~379-fold higher than sibeprenlimab, ~26-fold higher than povetacicept (cross-study comparison)
• Half-life at steady state ~24.2 days, ~8.7-fold longer than povetacicept, ~2.6-fold longer than sibeprenlimab
• Phase 2 IgAN trial (JUNIPER) initiated, interim data expected 2027
• Registrational Phase 3 trial planned for first half of 2027
• Cash of $311 million as of March 31, 2026; runway into 1H 2028
• Company estimates IgAN as $20B+ potential U.S. market alone

Financial Impact

No revenue or financial guidance provided; $311M cash position supports development into 1H 2028

Risk Factors

• Interim Phase 1 data in healthy volunteers may not fully translate to IgAN patients
• Cross-study comparisons to competitors are not head-to-head and may overstate differentiation
• Phase 2/3 clinical or regulatory delays could push timelines
• IgAN is a competitive landscape with multiple anti-APRIL/BAFF agents in development

Market Snapshot

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

US Market Status